At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 400 enrolled
Drug / intervention
AQX-1125 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The FLAGSHIP Study: A 12-week Phase II Study to Evaluate the Efficacy and Safety of AQX-1125 Following Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD) by Targeting the SHIP1 Pathway
In Brief
A Phase 2 clinical trial evaluating AQX-1125 and Placebo for COPD. Completed, enrolled 400 participants across 8 sites in 8 countries.
Detailed Summary
The primary objective of this study is to evaluate the effect of 12 weeks of treatment with once daily administration of AQX-1125 compared to placebo in subjects following exacerbations of Chronic Obstructive Pulmonary Disease (COPD) by targeting the SHIP1 (Src Homology 2-containing Inositol-5'-Phosphatase 1) pathway.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesAustralia, Denmark, Finland, Hungary, New Zealand, Poland, Sweden, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedOct 2013
Primary CompletionJul 2015
Study CompletionDec 2015
TodayJul 2026
First PostedOct 7, 2013
Enrollment StartOct 1, 2013
Primary CompletionJul 1, 2015
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.7 years ago
Interventions
AQX-1125drug
Synthetic SHIP1 activator
Placebodrug
Placebo control